Loading organizations...
Viva Ventures Biotech Group is a specialized venture capital firm focused on biotechnology innovation. It strategically invests in early-stage, discovery-phase startups developing first-in-class drug candidates. The firm supports global biotech ventures with potential to advance novel therapeutic solutions and address significant unmet medical needs.
Established in 2008 by founder Jun Mao, the firm addresses the critical need for dedicated capital and guidance for nascent biotech companies. Mao recognized the substantial lead times and resource requirements in drug discovery. This founding insight positioned Viva Ventures Biotech Group as a pivotal early-stage investor, empowering scientists and entrepreneurs.
Promising biotech startups are primary beneficiaries of Viva Ventures Biotech Group, receiving essential funding and operational support to translate scientific breakthroughs into viable therapies. The firm's mission is to accelerate groundbreaking biotechnology development, contributing to global healthcare. Its vision centers on strategic investments leading to successful commercialization of transformative medical advancements.
Viva Ventures Biotech Group has 2 tracked investments across 2 companies. The latest tracked deal is $3.6M Seed in AmacaThera in October 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 3, 2019 | AmacaThera | $3.6M Seed | Viva Ventures Biotech Group | Grey SKY Venture Partners, Peter VAN DER Velden, Mba, M.sc. |
| Aug 1, 2018 | SQZ Biotech | $72.0M Series C | — | 8VC, ARCH Venture Partners, Flagship Ventures, NanoDimension, Polaris Partners, Marc Elia, Everblue, Zafrira Avnur, GV, Illumina Ventures, Invus, JDRF, NanoDimension, Orient Life, AMY Schulman |
